SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
News Jun 24, 2015
SOLVO Biotechnology and Hepregen Corporation have announced, at the 13th European Meeting of the International Society for the Study of Xenobiotics ("ISSX"), a co-marketing agreement between the companies. This agreement provides for the European marketing of Hepregen's human, monkey, rat and dog application-directed HepatoPac® and HepatoMuneT kits, which are used for liver metabolite analysis, transport studies and predictive and mechanistic toxicology studies.
These kits contain human or animal hepatocytes (liver cells) in Hepregen's proprietary micro-patterned, co-culture microtiter tissue culture plates. This agreement provides SOLVO with the opportunity to make services available to its customers using these Hepregen products as well as HepatoPac® B-CLEAR® products co-developed by Hepregen and Qualyst Transporter Solutions.
"Hepregen's technology is a welcome addition to our world-recognized portfolio of products and services associated with transporter protein analysis", said Erno Duda, SOLVO's chief executive officer. "As the transporter field matures, we see a growing need for physiologically relevant systems in addition to the established transfected models. Moreover, adding Hepregen's portfolio to ours provides us with an opportunity to broaden our offerings to customers into the important areas of drug metabolism and safety testing. Our partnership with Hepregen enhances SOLVO's ability to grow as a biotechnology enterprise."
Dr. Vincent Zurawski, Hepregen's president and chief executive, stated, "This marketing partnership represents another step in Hepregen's unceasing effort to make our application-directed products and associated services available to customers around the world," adding, "SOLVO's exceptional European sales capability is expected to dramatically augment our already growing European sales effort."
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation.
A computer-guided algorithm may help scientists find just the right spot to split a protein and then reassemble it to functionality, according to a new study. Researchers say this could be another step — perhaps even a dance step — toward using chemical and light signals to create new medical treatments and biosensors.READ MORE
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019